GenSight Biologics S.A.

Regulatory Filings • Nov 6, 2017

Press release

GenSight Biologics to Participate in Multiple Conferences in November

Paris, France, November 6, 2017, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will participate in the following industry, medical and investor conferences:

Ophthalmology Innovation Summit (OIS) @AAO

November 9, 2017 – New Orleans (USA)

Barrett Katz, MD, Chief Medical Officer, will present on November 9, 2017, at 8:47 am CDT, at the Hyatt Regency Hotel in New Orleans, LA, USA.

American Academy of Ophthalmology (AAO)

November 11-14, 2017 – New Orleans (USA)

Members of the management team will attend the conference at the Ernest N. Morial Convention Center in New Orleans, LA, USA, and host investigator, business development and investor meetings.

Stifel Healthcare Conference

November 14-15, 2017 – New York (USA)

Bernard Gilly, Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will present on November 15, 2017, at 2:45 pm ET, at the Lotte New York Palace Hotel in New York, NY, USA, and host investor meetings.

Contacts

GenSight Biologics

Thomas Gidoin Chief Financial Officer tgidoin@gensight-biologics.com +33 (0)1 76 21 72 20

RooneyPartners

Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

The Trout Group Investor Relations Chad Rubin crubin@troutgroup.com +1-646-378-2947

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.